Reprogram Biosciences Closes $6M Seed Financing

Reprogram Biosciences raised a seed round, bringing total funding to $6 million since its 2025 launch.

The preclinical oncology biotech is developing mRNA-based therapies for solid tumors.

Backers include Unshackled Ventures, 1517 Fund, and Narya.

The new capital should help advance the company’s early-stage cancer drug program.